RT Journal Article
SR Electronic
T1 Amelioration of muscular dystrophy phenotype in mdx mice by inhibition of Flt1
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 609735
DO 10.1101/609735
A1 Mayank Verma
A1 Yuko Shimizu-Motohashi
A1 Yoko Asakura
A1 James Ennen
A1 Jennifer Bosco
A1 Zhiwei Zou
A1 Guo-Hua Fong
A1 Serene Josiah
A1 Dennis Keefe
A1 Atsushi Asakura
YR 2019
UL http://biorxiv.org/content/early/2019/04/21/609735.abstract
AB Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disease in which the dystrophin coding for a membrane stabilizing protein is mutated. Recently, the vasculature has also shown to be perturbed in DMD and DMD model mdx mice. Data-mining DMD transcriptomics revealed the defects were correlated to a vascular endothelial growth factor (VEGF) signaling pathway. To reveal the relationship between DMD and VEGF signaling, mdx mice were crossed with constitutive (CAG/CreERTM:Flt1LoxP/LoxP) and endothelial cell-specific conditional gene knockout mice (Cdh5CreERT2:Flt1LoxP/LoxP) for Flt1 which is a decoy receptor for VEGF. Previous work demonstrated that heterozygous global Flt1 knockout mice increased vascular density and improved DMD phenotypes when crossed with DMD model mdx and mdx:utrn-/- mice. Here, we showed that while constitutive deletion of Flt1 is detrimental to the skeletal muscle function, endothelial cell-specific Flt1 deletion resulted in increased vascular density and improvement in the DMD-associated phenotype in the mdx mice. These decreases in pathology, including improved muscle histology and function, were recapitulated in mdx mice given anti-FLT1 peptides or monoclonal antibodies, which blocked VEGF-FLT1 binding. The histological and functional improvement of dystrophic muscle by FLT1 blockade provides a novel pharmacological strategy for the potential treatment of DMD.